£86.82

It has never been this cheap. We have no record of a lower price.

£87 today · cheaper than every other day in the last 3 months

FIGHTING LUNG CANCER THROUGH THE HER FA (Cancer Etiology, Diagnosis and Treatments)

View at Amazon

Price History & Forecast

Grey patches = out of stock. Cheaper = lower on the chart. Hover for exact prices.

Last 20 days · 20 data points (no recent data)

Historical
Generating forecast…
£87.33 £86.77 £86.89 £87.01 £87.14 £87.26 £87.38 25 July 2026 29 July 2026 03 August 2026 08 August 2026 13 August 2026
View at Amazon ↗

Price data last checked 71 day(s) ago - refreshing...

NEW HERE?

Amazon shows you one price. We show you all of them.

Tosheroon watches Amazon prices so you don't have to. Every product on Amazon has a price history — we make it visible. Set the price you'd actually pay, and we'll email you the second it gets there. No app, no account, one email.

WHAT'S ON THIS PAGE

↑ Price chart
when this has been cheap or pricey
↑ Forecast
where the price is heading next
↓ Statistics
all-time high & low, recent range
↑ Price alert
name your number, we'll email you

Price Distribution

Price distribution over 20 days • 1 price levels

Days at Price
20 days 0 5 10 15 20 £87 Days at Price

Price Analysis

Most common price: £87 (20 days, 100.0%)

Price range: £87 - £87

Price levels: 1 different prices over 20 days

Description

Lung cancer is the most common and most lethal malignancy world-wide, causing 1.4 million diseases every year. Half of non-small cell lung cancers (NSCLC) are diagnosed at such an advanced stage that a cure cannot be considered a realistic aim, and over 75% of cases selected for a curative treatment eventually relapse within five years. The 5-year overall survival rates are less than 20% for NSCLC patients. As a disease, NSCLC demands our maximum abilities as researchers, physicians, and care-givers, and a continuous updating of our knowledge. Conventional chemotherapy for advanced NSCLC does not provide a great long-term benefit in terms of survival. Accordingly, a different therapeutic approach has to be explored. The human epidermal growth factor family of surface receptors (HER) became a critical target to be investigated. The epidermal growth factor receptor (EGFR) is over-expressed in over 80% of non-small cell lung cancer. The presence of sensitising conformational mutations in the EGFR increases the efficacy of modern tyrosine kinase inhibitors against its inner portion (EGFR-TKI). The EGFR-TKIs greatly prolong disease-free survival of those patients harbouring sensitising EGFR mutations, and have been suggested as an essential tool in the therapeutic repertoire. This volume aims to serve as an updated compendium of biology and applications of anti-EGFR therapies, and offers a look at the future of anti-HER therapy in lung cancer. This volume exhaustively reviews and discusses: 1) the nature and significance of activating EGFR mutations, and those clinical and pathological phenomena related to HER alterations; 2) the most common laboratory methodologies to study EGFR, and the future of HER analysis; 3) the right time to analyse EGFR mutations and evolutionary changes in the HER; 4) EGFR-TKI application in unselected and selected NSCLC patients; 5) upcoming anti-HER therapies; 6) the eventual role of anti-HER therapies in early NSCLC; 7) mechanisms of acquired resistance to anti-HER therapies, and experimental and conventional strategies to bypass them; 8) the application of anti-HER therapies in other malignancies. This book is an indispensable handbook for all those specialists devoted to the diagnosis and management of lung cancer.

Product Specifications

Format
hardcover
Domain
Amazon UK
Release Date
01 September 2014
Listed Since
20 April 2014

Barcode

No barcode data available

Similar Products You Might Like

Lung Cancer
98% match

Lung Cancer

Wiley

£90.53 05 Oct 2026
Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews: 75 (Methods in Molecular Medicine, 75)
98% match

Lung Cancer: Volume 2: Diagnostic and Therapeutic Methods and Reviews: 75 (Methods in Molecular Medicine, 75)

Humana

£91.67 17 Sep 2026
Lung Cancer and Personalized Medicine: Current Knowledge and Therapies: 893 (Advances in Experimental Medicine and Biology, 893)
98% match

Lung Cancer and Personalized Medicine: Current Knowledge and Therapies: 893 (Advances in Experimental Medicine and Biology, 893)

Springer

£76.42 01 Oct 2026
Lung Cancer: Treatment and Research: 170
98% match

Lung Cancer: Treatment and Research: 170

Springer

£122.96 11 Sep 2026
Lung Cancer Volume 2 - Diagnostic and Therapeutic Methods
97% match

Lung Cancer Volume 2 - Diagnostic and Therapeutic Methods

Humana

£78.82 06 Oct 2026
Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)
97% match

Advances in Respiratory Cancerogenesis: 911 (Advances in Experimental Medicine and Biology, 911)

Springer

£74.55 12 Sep 2026
Lung Cancer: Treatment and Research - Springer Clinical Guide
97% match

Lung Cancer: Treatment and Research - Springer Clinical Guide

Springer

£128.11 02 Oct 2026
Lung Cancer (MD Anderson Cancer Care Series)
97% match

Lung Cancer (MD Anderson Cancer Care Series)

Springer

£60.23 12 Sep 2026
Lung Cancer: A Comprehensive Overview (Cancer Etiology, Diagnosis and Treatments)
97% match

Lung Cancer: A Comprehensive Overview (Cancer Etiology, Diagnosis and Treatments)

Nova Science Publishers Inc

£95.00 18 Sep 2026
Targeted Therapies for Lung Cancer (Current Cancer Research)
97% match

Targeted Therapies for Lung Cancer (Current Cancer Research)

Springer

£97.48 15 Aug 2026
McGraw-Hill Lung Cancer: Standards of Care Medical Guide
97% match

McGraw-Hill Lung Cancer: Standards of Care Medical Guide

McGraw-Hill Education

£123.98 02 Oct 2026
Lung Cancer Treatment (Cancer Etiology, Diagnosis and Treatments)
97% match

Lung Cancer Treatment (Cancer Etiology, Diagnosis and Treatments)

£90.99 12 Sep 2026
Molecular Targeted Therapy of Lung Cancer
97% match

Molecular Targeted Therapy of Lung Cancer

Springer

£113.70 12 Oct 2026
Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)
97% match

Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)

Humana

£91.30 19 Sep 2026
Advances in Clinical Science: 878 (Advances in Experimental Medicine and Biology, 878)
97% match

Advances in Clinical Science: 878 (Advances in Experimental Medicine and Biology, 878)

Springer

£73.85 23 Sep 2026
Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)
97% match

Lung Cancer: Volume 1: Molecular Pathology Methods and Reviews: 74 (Methods in Molecular Medicine, 74)

Humana

£84.03 05 Oct 2026
Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management: 890 (Advances in Experimental Medicine and Biology, 890)
97% match

Lung Cancer and Personalized Medicine: Novel Therapies and Clinical Management: 890 (Advances in Experimental Medicine and Biology, 890)

Springer

£76.42 06 Oct 2026
Lung Cancer Therapy Annual 7
97% match

Lung Cancer Therapy Annual 7

CRC Press

£102.23 30 Sep 2026
Lung Cancer, Part II, An Issue of Clinics in Chest Medicine: Volume 41-2 (The Clinics: Internal Medicine, Volume 41-2)
97% match

Lung Cancer, Part II, An Issue of Clinics in Chest Medicine: Volume 41-2 (The Clinics: Internal Medicine, Volume 41-2)

Elsevier

£74.55 23 Sep 2026
Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies (Volume 1) (Breaking Tolerance to Antibody-Mediated Immunotherapy, Volume 1)
97% match

Novel Sensitizing Agents for Therapeutic Anti-EGFR Antibodies (Volume 1) (Breaking Tolerance to Antibody-Mediated Immunotherapy, Volume 1)

Elsevier

£118.77 04 Oct 2026
Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management
97% match

Lung Cancer: An Evidence-Based Approach to Multidisciplinary Management

Elsevier

£138.02 15 Aug 2026
Oxford Case Histories in Lung Cancer
97% match

Oxford Case Histories in Lung Cancer

Oxford University Press

£76.00 26 Sep 2026
Lung Cancer, An Issue of Clinics in Chest Medicine (Volume 32-4) (The Clinics: Internal Medicine, Volume 32-4)
97% match

Lung Cancer, An Issue of Clinics in Chest Medicine (Volume 32-4) (The Clinics: Internal Medicine, Volume 32-4)

Elsevier

£62.41 23 Sep 2026
Lung Cancer, An Issue of Hematology/Oncology Clinics (Volume 31-1) (The Clinics: Internal Medicine, Volume 31-1)
97% match

Lung Cancer, An Issue of Hematology/Oncology Clinics (Volume 31-1) (The Clinics: Internal Medicine, Volume 31-1)

Elsevier

£69.11 13 Sep 2026